Home> Products> sulfonylurea component

{ "products": [ { "_id": "6911af10f122e2a45d230b07", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Sitagliptin 50 mg, Metformin Hydrochloride 1000 mg & Glimepirde 2 mg", "description": "Sitagliptin 50 mg, Metformin Hydrochloride 1000 mg, and Glimepiride 2 mg is a triple-combination oral anti-diabetic medication formulated to achieve optimal blood sugar control in adults with Type 2 Diabetes Mellitus (T2DM). This unique blend brings together three complementary agents — Sitagliptin (a DPP-4 inhibitor), Metformin (a biguanide), and Glimepiride (a sulfonylurea) — that work through distinct mechanisms to enhance glucose regulation, improve insulin sensitivity, and support overall metabolic balance.\n\nThis advanced combination therapy is prescribed when monotherapy or dual therapy fails to achieve adequate glycemic control. It helps reduce both fasting plasma glucose (FPG) and postprandial glucose (PPG) levels, promoting stable long-term glycemic management.\n\nUses of Sitagliptin + Metformin + Glimepiride\n\nThis fixed-dose combination is primarily indicated for the management of Type 2 Diabetes Mellitus in adults. It is especially beneficial for patients whose blood sugar levels remain uncontrolled despite treatment with Metformin and Glimepiride or Metformin and Sitagliptin alone.\n\nIts main objectives include:\n\nControlling elevated blood glucose levels in adults with Type 2 diabetes\n\nReducing the risk of diabetes-related complications such as neuropathy, nephropathy, and cardiovascular diseases\n\nSupporting better insulin utilization by the body\n\nComplementing diet, exercise, and lifestyle modification to maintain optimal glycemic balance\n\nMechanism of Action\n\nEach component of this combination plays a vital role in maintaining blood sugar control:\n\nSitagliptin (50 mg) – A Dipeptidyl Peptidase-4 (DPP-4) inhibitor that enhances the activity of incretin hormones. These hormones stimulate insulin release and suppress glucagon production when blood glucose levels rise, thereby improving post-meal glucose control.\n\nMetformin Hydrochloride (1000 mg) – A biguanide that lowers glucose production in the liver and increases the body’s sensitivity to insulin. It also decreases intestinal glucose absorption, making it an essential first-line therapy in diabetes management.\n\nGlimepiride (2 mg) – A sulfonylurea that stimulates pancreatic beta cells to release more insulin, especially when blood glucose levels are high. It works synergistically with Metformin and Sitagliptin for more effective glycemic control.\n\nKey Benefits\n\nTriple Mechanism for Superior Control:\nBy combining three potent agents, the medication addresses multiple pathways of glucose regulation—insulin secretion, insulin sensitivity, and hepatic glucose output—resulting in comprehensive and consistent control of blood sugar levels.\n\nEffective Glycemic Stability:\nThe combination helps maintain target HbA1c levels and reduces both fasting and post-meal glucose spikes without significant weight gain when used with proper diet and exercise.\n\nReduced Risk of Diabetic Complications:\nLong-term blood sugar control minimizes the risk of complications such as kidney disease, vision problems, nerve damage, and heart conditions associated with uncontrolled diabetes.\n\nConvenient Fixed-Dose Formulation:\nCombining three medications into a single tablet simplifies dosing schedules, improves patient adherence, and reduces pill burden, which is crucial for long-term treatment success.\n\nImproved Insulin Efficiency:\nEnhances the body's natural insulin response and glucose metabolism, allowing for smoother daily energy levels and reduced fatigue associated with hyperglycemia.\n\nPossible Side Effects\n\nWhile this combination is generally well tolerated, some patients may experience side effects, especially at the beginning of therapy. Common and rare side effects include:\n\nHypoglycemia (low blood sugar): More likely when meals are skipped or during excessive physical exertion. Symptoms include sweating, dizziness, and rapid heartbeat.\n\nGastrointestinal disturbances: Such as nausea, vomiting, diarrhea, abdominal discomfort, or loss of appetite (mostly due to Metformin).\n\nHeadache or Weakness: Usually mild and transient.\n\nAllergic reactions: Rarely, rash or itching may occur.\n\nLactic Acidosis (rare but serious): A potential complication of Metformin, particularly in patients with kidney impairment or excessive alcohol consumption.\n\nWeight gain: Mild weight gain may occur due to Glimepiride’s insulin-enhancing effect.\n\nPrecautions:\n\nRegular monitoring of blood sugar levels and kidney function is essential.\n\nAvoid alcohol and consult a doctor before using this medicine if you have liver or kidney disease.\n\nThe medication should not be used in patients with Type 1 diabetes or diabetic ketoacidosis.\n\nConclusion\n\nThe combination of Sitagliptin 50 mg, Metformin Hydrochloride 1000 mg, and Glimepiride 2 mg represents a powerful and balanced therapy for adults with Type 2 Diabetes Mellitus, especially those requiring triple-drug intervention to achieve desired glycemic control. Its multi-targeted approach ensures effective management of both fasting and postprandial glucose levels, thereby improving long-term metabolic health and reducing the risk of complications.", "price": 295.0, "discountamount": 89.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2197, "imageuri": "https://productimages.withfloats.com/actual/6911af137e4c90e1dc453884.png", "tileimageuri": "https://productimages.withfloats.com/tile/6911af137e4c90e1dc453884.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-11-10T09:23:28.795Z", "updatedon": "2025-12-09T05:58:38.882Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/sitagliptin-50-mg-metformin-hydrochloride-1000-mg-glimepirde-2-mg/2197", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ST GLIPTIN GM 50+1000+2 ", "category": "DIABETIC RANGE", "tags": [ "Sitagliptin 50 mg, Metformin Hydrochloride 1000 mg, and Glimepiride 2 mg", "anti-diabetic medication", "blood sugar control", "Type 2 Diabetes Mellitus" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68fcb453ba48b3ee8857fd47", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Sitagliptin Phosphate Monhydrate 64.25 mg, Sitagliptin 50 mg, Metformin Hydrochloride 1000 mg & Glimepirde 1 mg", "description": "ST GLIPTIN GM is a high-quality, fixed-dose combination oral antidiabetic medication containing Sitagliptin 50 mg, Metformin Hydrochloride 1000 mg, and Glimepiride 1 mg. This triple-combination therapy is specifically formulated to provide effective glycemic control in adults with type 2 diabetes mellitus (T2DM) who require multiple agents to achieve adequate blood sugar control.\nST GLIPTIN GM works through complementary mechanisms to target the core pathophysiological defects of T2DM—insulin resistance, impaired insulin secretion, and increased hepatic glucose output—making it an ideal choice for patients requiring intensified therapy.\nKey Indications:\nST GLIPTIN GM is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when dual therapy with any two of the individual components (Sitagliptin, Metformin, or Glimepiride) does not provide adequate control.\nMechanism of Action:\nSitagliptin (50 mg):\nA Dipeptidyl Peptidase-4 (DPP-4) inhibitor that enhances the levels of active incretin hormones (GLP-1 and GIP), increasing insulin release and decreasing glucagon secretion in a glucose-dependent manner.\nMetformin Hydrochloride (1000 mg):\nA biguanide that improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake.\nGlimepiride (1 mg):\nA sulfonylurea that stimulates pancreatic β-cells to secrete insulin, thereby reducing blood glucose levels.\nThe combination targets multiple metabolic pathways to provide synergistic and sustained blood glucose control.\nDosage and Administration:\nRecommended Dose:\nOne tablet daily, preferably with meals to reduce gastrointestinal side effects.\nIndividualization Required:\nDosage should be tailored based on patient response, renal function, and physician assessment.\nRenal Monitoring:\nBaseline and periodic assessment of renal function is advised, particularly due to the metformin component.\nKey Benefits of ST GLIPTIN GM 50/1000/1:\nTriple Mechanism of Action:\nTargets insulin resistance, insufficient insulin secretion, and excessive hepatic glucose production.\nEnhanced Glycemic Control:\nEffective in achieving and maintaining HbA1c targets.\nOnce-Daily Convenience:\nImproves adherence by reducing pill burden in patients requiring combination therapy.\nWeight Neutral to Modest Reduction:\nMetformin and sitagliptin components support weight neutrality.\nLow Hypoglycemia Risk:\nSitagliptin and metformin carry minimal hypoglycemia risk; however, glimepiride may increase the risk—monitor accordingly.\nSafety and Precautions:\nHypoglycemia:\nMay occur, particularly due to the glimepiride component. Educate patients on recognizing and managing low blood sugar.\nLactic Acidosis:\nA rare but serious complication of metformin. Avoid in patients with significant renal impairment or conditions predisposing to hypoxia.\nRenal Function:\nDose adjustment or discontinuation may be needed based on renal function.\nPancreatitis:\nRare reports with DPP-4 inhibitors like sitagliptin. Discontinue if suspected.\nAllergic Reactions:\nDiscontinue use if hypersensitivity reactions occur.\nPossible Side Effects:\nWhile ST GLIPTIN GM is generally well-tolerated, some patients may experience:\nNausea\nDiarrhea\nHeadache\nHypoglycemia (especially in elderly or with missed meals)\nAbdominal discomfort\nUpper respiratory tract infections\nDizziness\nFlatulence\nIf any side effects persist or worsen, seek immediate medical advice.\nStorage Instructions:\nStore at a temperature below 30°C.\nProtect from moisture and direct sunlight.\nKeep out of reach of children.\nWhy Choose ST GLIPTIN GM 50/1000/1?\nST GLIPTIN GM provides a powerful and synergistic combination of three well-established antidiabetic agents in a single, convenient daily dose. It offers a comprehensive approach to managing type 2 diabetes by addressing multiple metabolic abnormalities with a focus on safety, efficacy, and patient compliance. Manufactured under stringent GMP-certified conditions, ST GLIPTIN GM ensures quality, reliability, and therapeutic confidence for both patients and prescribers.", "price": 285.0, "discountamount": 86.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2188, "imageuri": "https://productimages.withfloats.com/actual/68fcb456f31288eaa96accfa.png", "tileimageuri": "https://productimages.withfloats.com/tile/68fcb456f31288eaa96accfa.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-10-25T11:28:19.425Z", "updatedon": "2025-12-09T06:06:38.819Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/sitagliptin-phosphate-monhydrate-64-25-mg-sitagliptin-50-mg-metformin-hydrochloride-1000-mg-glimepirde-1-mg/2188", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ST GLIPTIN GM 50+1000+1", "category": "DIABETIC RANGE", "tags": [ "Sitagliptin 50 mg", "Sitagliptin 50 mg, Metformin Hydrochloride 1000 mg, and Glimepiride 1 mg", "type 2 diabetes mellitus (T2DM)", "blood sugar control" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68d51d9a26579f4bc195771a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Glimepiride IP1 mg, Voglibose IP 0.2 MG & Metformin Hydrochloride IP 500 mg ", "description": "GLIMITERIS MV1 0.2 is an advanced fixed-dose combination (FDC) medication designed for adults with Type 2 Diabetes Mellitus (T2DM) who require more than lifestyle modifications or single/dual therapy to maintain optimal blood sugar levels. This innovative formulation brings together the power of three well-established antidiabetic agents—Glimepiride (1 mg), Voglibose (0.2 mg), and Metformin Hydrochloride SR (500 mg)—to provide comprehensive glycemic control.\n\nIt is particularly effective for patients struggling with postprandial hyperglycemia, fasting glucose regulation, and HbA1c reduction, making it a preferred choice in cases of poorly controlled diabetes.\n\n \n\nMechanism of Action\nThe therapeutic benefit of GLIMITERIS MV1 0.2 comes from the unique synergy of its three components, each targeting different aspects of glucose metabolism:\n\n1. Glimepiride (1 mg) – Sulfonylurea\nStimulates insulin secretion by activating pancreatic beta cells.\n\nProvides a long-lasting effect with comparatively lower hypoglycemia risk than older sulfonylureas.\n\nHelps reduce both fasting and postprandial glucose levels.\n\n2. Voglibose (0.2 mg) – Alpha-Glucosidase Inhibitor\nDelays the breakdown and absorption of carbohydrates in the intestine.\n\nMinimizes post-meal glucose spikes (PPBG).\n\nActs locally in the gut and has minimal systemic absorption, which reduces systemic side effects.\n\n3. Metformin Hydrochloride SR (500 mg) – Biguanide\nDecreases hepatic glucose production (gluconeogenesis).\n\nImproves peripheral insulin sensitivity, enhancing glucose uptake in muscles.\n\nDoes not cause hypoglycemia on its own.\n\nThe sustained-release (SR) formulation ensures extended control and reduces gastrointestinal side effects.\n\n \n\nIndications\nGLIMITERIS MV1 0.2 is indicated for:\n\nAdults with Type 2 Diabetes Mellitus.\n\nPatients inadequately controlled with monotherapy or dual therapy.\n\nManagement of fasting and postprandial hyperglycemia.\n\nLong-term HbA1c reduction as part of a comprehensive diabetes care plan.\n\n \n\nKey Benefits\n✅ Comprehensive Blood Sugar Control – Acts on fasting, post-meal, and long-term HbA1c levels.\n✅ Postprandial Spike Management – Voglibose effectively controls carbohydrate-induced sugar surges.\n✅ Reduced Pill Burden – Combines three medicines into a single tablet.\n✅ Lower Hypoglycemia Risk – Metformin and Voglibose balance out Glimepiride’s insulin-secreting effect.\n✅ Weight Management Support – Metformin may promote modest weight loss or prevent weight gain.\n✅ Improved Tolerability – SR formulation of Metformin enhances gastrointestinal comfort.\n\n \n\nDosage and Administration\nRecommended dose: One tablet once or twice daily with meals, or as directed by the physician.\n\nAdministration tips:\n\nTake with the first bite of a main meal to maximize Voglibose’s effect.\n\nSwallow whole with water; do not crush or chew the SR tablet.\n\nDose adjustments: Based on blood sugar monitoring, clinical response, and renal/hepatic function.\n\n \n\nContraindications\nGLIMITERIS MV1 0.2 is not suitable for patients with:\n\nType 1 diabetes or diabetic ketoacidosis.\n\nSevere renal impairment (eGFR <30 mL/min/1.73 m²).\n\nHepatic dysfunction.\n\nSevere gastrointestinal diseases.\n\nHistory of lactic acidosis.\n\nHypersensitivity to Glimepiride, Voglibose, or Metformin.\n\nPregnancy and lactation (unless strictly advised by a physician).\n\n \n\nWarnings and Precautions\nHypoglycemia: Risk is higher when combined with other antidiabetics or with missed meals.\n\nLactic Acidosis: A rare but life-threatening effect of Metformin—renal function monitoring is essential.\n\nGI Side Effects: Voglibose and Metformin may cause bloating, flatulence, or diarrhea (usually temporary).\n\nVitamin B12 Monitoring: Long-term Metformin use may reduce B12 absorption.\n\nLiver and Kidney Function: Regular monitoring is recommended for safe long-term use.\n\n \n\nAdverse Effects\nCommon:\nGlimepiride: Mild hypoglycemia, dizziness, slight weight gain.\n\nVoglibose: Gas, abdominal discomfort, mild diarrhea.\n\nMetformin SR: Nausea, bloating, metallic taste, loose stools.\n\nRare but Serious:\nLactic acidosis (from Metformin).\n\nSevere hypoglycemia (especially if meals are skipped).\n\nAllergic reactions such as rash, itching, or swelling.\n\nElevated liver enzymes.\n\nSeek medical attention if symptoms such as rapid breathing, confusion, severe fatigue, or muscle pain occur.\n\n \n\nDrug Interactions\nIncreased hypoglycemia risk: With insulin, beta-blockers, and sulfonylureas.\n\nReduced Metformin efficacy: With corticosteroids, estrogens, and diuretics.\n\nLactic acidosis risk: Higher with alcohol or iodinated contrast agents. ", "price": 263.0, "discountamount": 80.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2182, "imageuri": "https://productimages.withfloats.com/actual/68d51d9cdf1a4ca2c252370a.png", "tileimageuri": "https://productimages.withfloats.com/tile/68d51d9cdf1a4ca2c252370a.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-09-25T10:46:50.098Z", "updatedon": "2025-12-02T06:31:16.051Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glimepiride-ip1-mg-voglibose-ip-0-2-mg-metformin-hydrochloride-ip-500-mg-/2182", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIMITERIS MV1 0.2", "category": "", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "668e8611b9f7300708fe1240", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIOGLIMITERIS 1/0.2 ", "description": "TRIOGLIMITERIS 1/0.2 \nVoglibose 0.2 mg, Glimepiride 1 mg & Metformin Hydrochloride 500 mg\nIntroduction\n\nTRIOGLIMITERIS 1/0.2 is a combination medication containing Voglibose, Glimepiride, and Metformin Hydrochloride. It is primarily used in the management of type 2 diabetes mellitus to improve glycemic control through different mechanisms of action targeting glucose metabolism.\n\nComposition\n\nVoglibose (0.2 mg): An alpha-glucosidase inhibitor that delays the digestion of carbohydrates in the intestine, thereby reducing postprandial blood glucose levels.\nGlimepiride (1 mg): A sulfonylurea derivative that stimulates insulin release from pancreatic beta cells, enhancing glucose uptake in peripheral tissues.\nMetformin Hydrochloride (500 mg): A biguanide that decreases hepatic glucose production, improves insulin sensitivity in peripheral tissues, and reduces intestinal glucose absorption.\nMechanism of Action\n\nTRIOGLIMITERIS 1/0.2 combines the actions of its components to achieve optimal glycemic control:\n\nVoglibose: Inhibits alpha-glucosidase enzymes in the intestine, delaying carbohydrate digestion and reducing the absorption of glucose after meals.\nGlimepiride: Stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, thereby lowering blood glucose levels.\nMetformin Hydrochloride: Decreases hepatic glucose production through suppression of gluconeogenesis and enhances peripheral glucose uptake and utilization by improving insulin sensitivity.\nIndications\n\nTRIOGLIMITERIS 1/0.2 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults when diet, exercise, and monotherapy with metformin or sulfonylureas alone are not sufficient.\nDosage and Administration\n\nThe typical dosage of TRIOGLIMITERIS 1/0.2 is one tablet taken orally with meals, usually once or twice daily.\nDosage adjustments may be required based on individual patient response, blood glucose levels, and renal function.\nIt is essential to adhere to the prescribed dosage regimen to achieve optimal therapeutic outcomes.\nSide Effects\n\nCommon side effects of TRIOGLIMITERIS 1/0.2 may include:\n\nHypoglycemia (especially when used in combination with insulin or other antidiabetic medications)\nGastrointestinal disturbances (such as nausea, vomiting, diarrhea, or abdominal discomfort)\nWeight gain (mainly associated with sulfonylureas)\nMore severe side effects can include:\n\nAllergic reactions (rash, itching, swelling)\nLactic acidosis (rare but serious adverse effect associated with metformin use)\nHepatic dysfunction (monitor liver function tests periodically)\nPrecautions\n\nUse with caution in patients with renal impairment, hepatic dysfunction, or other significant medical conditions that may affect drug metabolism or excretion.\nRegular monitoring of blood glucose levels, renal function, and liver function is recommended during treatment with TRIOGLIMITERIS 1/0.2.\nAvoid use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.\nDrug Interactions\n\nTRIOGLIMITERIS 1/0.2 may interact with other medications affecting blood glucose levels, such as insulin, other oral antidiabetic agents, or drugs that affect renal function or hepatic metabolism. Close monitoring and dose adjustments may be necessary.\nConclusion\n\nTRIOGLIMITERIS 1/0.2 provides a comprehensive approach to managing type 2 diabetes mellitus by combining Voglibose, Glimepiride, and Metformin Hydrochloride. This combination targets different aspects of glucose metabolism, enhancing insulin secretion, reducing hepatic glucose production, and delaying carbohydrate absorption in the intestine. Proper dosage, administration, and monitoring for side effects are essential to achieve and maintain optimal glycemic control in diabetic patients using TRIOGLIMITERIS 1/0.2. Consultation with a healthcare provider is recommended for personalized treatment plans and management of diabetes with this medication.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 195.0, "discountamount": 58.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "500 mg", "0.2 mg", "one tablet", "Weight gain", "Glimepiride 1", "metformin use", "Proper dosage", "Glimepiride (1", "dosage regimen", "typical dosage", "renal function", "insulin release", "drug metabolism", "Lactic acidosis", "Close monitoring", "dose adjustments", "renal impairment", "diabetic patients", "insulin secretion", "different aspects", "Drug Interactions", "other medications", "Regular monitoring", "Dosage adjustments", "Allergic reactions", "peripheral tissues", "hepatic metabolism", "glucose metabolism", "insulin sensitivity", "healthcare provider", "Hepatic dysfunction", "Common side effects", "abdominal discomfort", "different mechanisms", "liver function tests", "diabetic ketoacidosis", "pancreatic beta cells", "combination medication", "carbohydrate digestion", "comprehensive approach", "serious adverse effect", "Metformin Hydrochloride", "carbohydrate absorption", "sulfonylurea derivative", "glucose-dependent manner", "optimal glycemic control", "type 1 diabetes mellitus", "type 2 diabetes mellitus", "More severe side effects", "alpha-glucosidase enzymes", "peripheral glucose uptake", "hepatic glucose production", "alpha-glucosidase inhibitor", "individual patient response", "personalized treatment plans", "optimal therapeutic outcomes", "Gastrointestinal disturbances", "intestinal glucose absorption", "other antidiabetic medications", "other oral antidiabetic agents", "postprandial blood glucose levels", "other significant medical conditions" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1939, "imageuri": "https://productimages.withfloats.com/actual/668e86143a68154e11e7d822.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e86143a68154e11e7d822.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T13:01:05.875Z", "updatedon": "2025-12-06T07:43:06.317Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trioglimiteris-1-0-2-/1939", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIOGLIMITERIS 1/0.2 ", "category": "DIABETIC RANGE", "tags": [ "glimepiride 1mg+metformin 500mg+voglibose 0.2 mg", "Glimepiride 2mg Metformin 500mg Voglibose 0.2 mg b", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg", "voglibose glimepiride & metformin hydrochloride (s", "voglibose glimepiride + metformin hydrochloride us", "glimepiride 1mg+metformin 500mg+voglibose 0.3 mg", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg g", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6662cd3e870e7b20c49e689e", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VOGLIGOLD G3 M0.3 ", "description": "VOGLIGOLD G3 M0.3 \nVoglibose 0.3 mg, Glimepiride 3 mg & Metformin Hydrochloride 500 mg\nIntroduction to VOGLIGOLD G3 M0.3\nVOGLIGOLD G3 M0.3 is a combination medication designed for the effective management of type 2 diabetes mellitus. It contains three active ingredients: Voglibose 0.3mg, Glimepiride 3mg, and Metformin Hydrochloride 500mg. This multi-action formula targets different aspects of glucose regulation to provide comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nVoglibose 0.3mg\nVoglibose is an alpha-glucosidase inhibitor that works by:\n\nSlowing Carbohydrate Absorption: Voglibose inhibits the alpha-glucosidase enzyme in the small intestine, delaying the breakdown of complex carbohydrates into glucose. This helps to smooth out postprandial (after-meal) blood glucose peaks.\nGlimepiride 3mg\nGlimepiride is a sulfonylurea that helps control blood sugar by:\n\nStimulating Insulin Secretion: Glimepiride stimulates the pancreas to release more insulin, which helps lower blood sugar levels, particularly after meals.\nMetformin Hydrochloride 500mg\nMetformin is a biguanide that helps lower blood sugar levels through several mechanisms:\n\nReducing Hepatic Glucose Production: Metformin decreases the amount of glucose produced by the liver.\nImproving Insulin Sensitivity: It enhances the sensitivity of muscle cells to insulin, promoting better glucose uptake and utilization.\nDecreasing Intestinal Absorption of Glucose: Metformin reduces the absorption of glucose from the gastrointestinal tract.\nBenefits of VOGLIGOLD G3 M0.3\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Voglibose, Glimepiride, and Metformin effectively manages both fasting and postprandial blood sugar levels.\nEnhanced Insulin Secretion and Sensitivity: Glimepiride enhances insulin secretion, while Metformin improves insulin sensitivity, and Voglibose slows carbohydrate absorption.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: The risk of hypoglycemia is minimized due to the complementary actions of the three components.\nWeight Neutrality: Metformin and Voglibose are generally weight neutral, making this combination favorable for patients concerned about weight gain associated with diabetes medications.\nHow to Use VOGLIGOLD G3 M0.3\nDosage and Administration\nRecommended Dosage: The typical dosage is one tablet taken once or twice daily, as prescribed by your healthcare provider.\nAdministration: Take the tablet with meals to reduce gastrointestinal side effects and enhance the absorption of Metformin. Swallow the tablet whole with a glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VOGLIGOLD G3 M0.3 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vogligold-g3-m0-3-134319", "price": 185.0, "discountamount": 55.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "meal", "diet", "Order", "glass", "water", "EMAIL", "liver", "adults", "amount", "Fasting", "readings", "patients", "pancreas", "Low Risk", "exercise", "breakdown", "same time", "biguanide", "Decreasing", "one tablet", "Guidelines", "Glimepiride", "Adjustments", "weight gain", "information", "utilization", "Optimal Use", "best results", "Introduction", "sterispharma", "sulfonylurea", "Hypoglycemia", "muscle cells", "sterisonline", "CALL/WHATSAPP", "Voglibose 0.3", "Administration", "typical dosage", "glucose uptake", "treatment plan", "Consistent Use", "Key Components", "small intestine", "glycemic control", "three components", "VOGLIGOLD G3 M0.3", "different aspects", "Weight Neutrality", "several mechanisms", "glucose regulation", "Regular monitoring", "Recommended Dosage", "blood glucose peaks", "Insulin Sensitivity", "healthcare provider", "diabetes medications", "effective management", "multi-action formula", "complex carbohydrates", "Intestinal Absorption", "complementary actions", "gastrointestinal tract", "combination medication", "Metformin Hydrochloride", "Carbohydrate Absorption", "alpha-glucosidase enzyme", "three active ingredients", "type 2 diabetes mellitus", "Enhanced Insulin Secretion", "Additional Health Benefits", "Hepatic Glucose Production", "alpha-glucosidase inhibitor", "gastrointestinal side effects", "Postprandial Glucose Management", "postprandial blood sugar levels", "comprehensive blood sugar control" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1519, "imageuri": "https://productimages.withfloats.com/actual/667d30b6c303c6d6ad136ea4.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d30b6c303c6d6ad136ea4.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T09:05:02.904Z", "updatedon": "2024-06-27T09:28:16.215Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/vogligold-g3-m0-3-/1519", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VOGLIGOLD G3 M0.3 ", "category": "DIABETIC RANGE", "tags": [ "glimepiride 3mg+metformin 500mg+voglibose 0.3 mg", "voglibose glimepiride + metformin hydrochloride us", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6662aa04db100e1fdc2dcb68", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE 100 ", "description": "VILDIABATE 100 \nVildagliptin (100mg)\nVILDIABATE 100 is a medication designed to manage type 2 diabetes mellitus by targeting specific aspects of glucose regulation. It contains Vildagliptin, an oral antidiabetic agent that belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors. Vildagliptin works by inhibiting the enzyme DPP-4, which is responsible for degrading incretin hormones like GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide).\n\nHere are key points about VILDIABATE 100:\n\nMechanism of Action: Vildagliptin acts by inhibiting DPP-4, thereby increasing the levels of GLP-1 and GIP. These hormones play crucial roles in glucose metabolism:\n\nGLP-1 stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner. It also inhibits glucagon secretion, reduces appetite, and slows gastric emptying.\nGIP enhances insulin release in response to meals, contributing to postprandial glucose control.\nBlood Sugar Control: By enhancing insulin secretion and reducing glucagon levels, VILDIABATE 100 helps lower blood sugar levels, especially after meals. This mechanism targets both fasting and postprandial hyperglycemia, contributing to overall glycemic control.\n\nDosage and Administration: VILDIABATE 100 is typically taken orally once daily, preferably with a meal to maximize its effects on postprandial glucose levels. The dosage may vary depending on individual needs and response to treatment. It's essential to follow your healthcare provider's instructions regarding dosage and timing.\n\nEfficacy and Safety: Clinical studies have demonstrated the efficacy of Vildagliptin in lowering HbA1c levels (a marker of long-term glucose control) and improving glycemic parameters. It is generally well-tolerated, with common side effects including headache, nasopharyngitis (inflammation of the nose and throat), and upper respiratory tract infections. Serious side effects are rare but may include pancreatitis or hypersensitivity reactions.\n\nCombination Therapy: VILDIABATE 100 may be prescribed as monotherapy or in combination with other antidiabetic medications such as metformin or sulfonylureas. Combining medications with different mechanisms of action can provide synergistic benefits in managing diabetes.\n\nMonitoring and Follow-Up: Regular monitoring of blood sugar levels, kidney function, and other relevant parameters is important during treatment with VILDIABATE 100. Your healthcare provider may adjust the dosage or add/modify other medications based on your response and individual needs.\n\nLifestyle Modifications: In addition to medication, lifestyle modifications such as a healthy diet, regular exercise, weight management, and avoiding tobacco and excessive alcohol intake are essential components of diabetes management.\n\nIn conclusion, VILDIABATE 100 containing Vildagliptin is an effective oral antidiabetic medication that helps regulate blood sugar levels in patients with type 2 diabetes. It acts by enhancing insulin secretion and reducing postprandial glucose levels, contributing to improved glycemic control. However, it should be used under medical supervision, and adherence to prescribed dosage and lifestyle recommendations is crucial for optimal diabetes management.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-100-133452\n\n\n\n\n\n", "price": 275.0, "discountamount": 82.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "nose", "GLP-1", "EMAIL", "class", "meals", "Order", "timing", "throat", "enzyme", "Safety", "Dosage", "marker", "tobacco", "fasting", "response", "addition", "appetite", "headache", "patients", "Efficacy", "metformin", "Follow-Up", "adherence", "treatment", "VILDIABATE", "conclusion", "key points", "information", "monotherapy", "healthy diet", "instructions", "sterisonline", "pancreatitis", "inflammation", "sterispharma", "HbA1c levels", "CALL/WHATSAPP", "sulfonylureas", "crucial roles", "Administration", "insulin release", "nasopharyngitis", "kidney function", "glucagon levels", "gastric emptying", "specific aspects", "Clinical studies", "individual needs", "regular exercise", "other medications", "Vildagliptin acts", "incretin hormones", "DPP-4) inhibitors", "weight management", "insulin secretion", "glucose metabolism", "glucose regulation", "glucagon secretion", "blood sugar levels", "Regular monitoring", "Combination Therapy", "glycemic parameters", "common side effects", "Blood Sugar Control", "medical supervision", "healthcare provider", "essential components", "synergistic benefits", "different mechanisms", "Serious side effects", "pancreatic beta cells", "dipeptidyl peptidase-4", "oral antidiabetic agent", "Lifestyle Modifications", "glucose-dependent manner", "excessive alcohol intake", "overall glycemic control", "type 2 diabetes mellitus", "lifestyle recommendations", "other relevant parameters", "long-term glucose control", "hypersensitivity reactions", "postprandial hyperglycemia", "optimal diabetes management", "postprandial glucose levels", "postprandial glucose control", "other antidiabetic medications", "upper respiratory tract infections", "effective oral antidiabetic medication", "glucose-dependent insulinotropic peptide" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1491, "imageuri": "https://productimages.withfloats.com/actual/6662aa0b364f23242470b3ca.png", "tileimageuri": "https://productimages.withfloats.com/tile/6662aa0b364f23242470b3ca.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T06:34:44.056Z", "updatedon": "2024-06-28T11:58:50.164Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/vildiabate-100-/1491", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VILDIABATE 100 ", "category": "DIABETIC RANGE", "tags": [ "VILDIABATE 100", "Vildagliptin (100mg)", "Vildagliptin 100 mg uses", "Vildagliptin 100 mg price", "Vildagliptin 100 mg SR brand Name", "Vildagliptin 100 mg brands in India", "", "Vildagliptin 100 mg generic medicine", "Vildagliptin 100 mg side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6661afd366170d1ff8cb4626", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIGLICLAGLAZE 60 ", "description": "TRIGLICLAGLAZE 60 \nGliclazide 60mg (SR) Pioglitazone 15mg and Metformin HCL 500mg(SR)\nTRIGLICLAGLAZE 60 is a combination medication designed to effectively manage type 2 diabetes mellitus by addressing multiple aspects of glucose regulation. It combines three key components: Gliclazide 60mg (SR), Pioglitazone 15mg, and Metformin HCI 500mg (SR), each contributing to improved blood sugar control through distinct mechanisms of action.\n\nGliclazide 60mg (SR): Gliclazide is a sulfonylurea medication that stimulates the pancreas to release insulin. This insulin release helps lower blood sugar levels, especially after meals, by facilitating glucose uptake into cells.\n\nPioglitazone 15mg: Pioglitazone belongs to the thiazolidinedione class and works by improving insulin sensitivity in peripheral tissues such as muscle and fat cells. Enhanced insulin sensitivity allows for better utilization of glucose, reducing insulin resistance and promoting more efficient blood sugar management.\n\nMetformin HCI 500mg (SR): Metformin is a biguanide medication that primarily works by reducing glucose production in the liver and increasing insulin sensitivity in muscle cells. It also improves glucose uptake by cells and reduces the absorption of glucose from the digestive tract.\n\nKey Benefits of TRIGLICLAGLAZE 60:\nComprehensive Glucose Control: By combining Gliclazide (SR), Pioglitazone, and Metformin HCI (SR), TRIGLICLAGLAZE 60 offers comprehensive control over blood sugar levels throughout the day.\n\nStimulates Insulin Release: Gliclazide's action in stimulating insulin release from the pancreas helps manage postprandial (after-meal) glucose spikes, contributing to overall glucose control.\n\nImproves Insulin Sensitivity: Pioglitazone enhances insulin sensitivity in tissues, leading to better glucose uptake and utilization by cells. This helps reduce insulin resistance, a common feature of type 2 diabetes.\n\nReduces Glucose Production: Metformin HCI lowers glucose production in the liver and improves insulin action in muscle cells, leading to lower fasting blood sugar levels and enhanced glucose utilization.\n\nExtended Release Formulation: The sustained-release formulations of Gliclazide and Metformin ensure a gradual and prolonged release of the medications, providing consistent blood sugar control and minimizing the risk of hypoglycemia or hyperglycemia.\n\nDosage and Administration:\nTRIGLICLAGLAZE 60 is typically taken orally once or twice daily, with meals to reduce gastrointestinal side effects.\nDosage adjustments may be required based on blood sugar levels and individual response to treatment. Follow your healthcare provider's instructions.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/trigliclaglaze-60-134279", "price": 155.0, "discountamount": 47.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "SR", "day", "risk", "meals", "Order", "liver", "EMAIL", "gradual", "fasting", "pancreas", "Enhanced", "treatment", "fat cells", "absorption", "information", "medications", "muscle cells", "Pioglitazone", "sterisonline", "Key Benefits", "hypoglycemia", "instructions", "sterispharma", "postprandial", "hyperglycemia", "CALL/WHATSAPP", "Metformin HCL", "Metformin HCI", "Administration", "glucose uptake", "TRIGLICLAGLAZE", "common feature", "glucose spikes", "insulin action", "insulin release", "Gliclazide 60mg", "digestive tract", "multiple aspects", "prolonged release", "Dosage adjustments", "peripheral tissues", "blood sugar levels", "glucose production", "insulin resistance", "glucose regulation", "distinct mechanisms", "healthcare provider", "individual response", "glucose utilization", "insulin sensitivity", "three key components", "biguanide medication", "comprehensive control", "combination medication", "sulfonylurea medication", "thiazolidinedione class", "overall glucose control", "type 2 diabetes mellitus", "Extended Release Formulation", "Comprehensive Glucose Control", "gastrointestinal side effects", "sustained-release formulations", "consistent blood sugar control", "efficient blood sugar management" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1485, "imageuri": "https://productimages.withfloats.com/actual/6661afd7f21358d53af3cd71.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661afd7f21358d53af3cd71.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:47:15.16Z", "updatedon": "2024-06-28T12:12:27Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trigliclaglaze-60-/1485", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIGLICLAGLAZE 60 ", "category": "DIABETIC RANGE", "tags": [ "TRIGLICLAGLAZE 60", "Gliclazide 60mg (SR)", "Pioglitazone 15mg", "Metformin HCL 500mg(SR)", "Metformin SR 500mg uses", "Metformin SR 500 price", "Metformin SR 500 side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6661af452bed1f08484d625b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIGLICLAGLAZE 30 ", "description": "TRIGLICLAGLAZE 30 \nGliclazide (SR) Pioglitazone and Metformin HCL (SR)\nTRIGLICLAGLAZE 30 is a combination medication formulated to manage type 2 diabetes mellitus effectively. It combines three key components: Gliclazide (SR), Pioglitazone, and Metformin HCI (SR), each targeting different aspects of glucose regulation to achieve optimal blood sugar control.\n\nGliclazide (SR): Gliclazide is a sulfonylurea medication that works by stimulating the pancreas to release insulin, which helps lower blood sugar levels. The sustained-release (SR) formulation ensures a gradual and prolonged release of the medication, providing consistent glucose-lowering effects throughout the day.\n\nPioglitazone: Pioglitazone belongs to the thiazolidinedione class of drugs and enhances insulin sensitivity in muscle and fat tissues. By improving the body's response to insulin, Pioglitazone helps reduce insulin resistance and promotes better glucose utilization by cells.\n\nMetformin HCI (SR): Metformin is a biguanide medication that works primarily by reducing glucose production in the liver and increasing insulin sensitivity in peripheral tissues. The sustained-release formulation ensures a gradual release of Metformin, minimizing gastrointestinal side effects and providing extended blood sugar control.\n\nKey Benefits of TRIGLICLAGLAZE 30:\nComprehensive Glucose Control: The combination of Gliclazide (SR), Pioglitazone, and Metformin HCI (SR) targets multiple pathways involved in glucose metabolism. This comprehensive approach helps achieve better overall blood sugar control throughout the day.\n\nStimulates Insulin Release: Gliclazide stimulates insulin secretion from the pancreas, especially after meals, which is crucial for managing postprandial (after-meal) glucose spikes.\n\nImproves Insulin Sensitivity: Pioglitazone enhances insulin sensitivity in muscle and fat tissues, allowing for better glucose uptake and utilization by cells. This action helps reduce insulin resistance, a hallmark of type 2 diabetes.\n\nReduces Hepatic Glucose Production: Metformin HCI (SR) reduces the production of glucose in the liver, helping to lower fasting blood sugar levels and prevent excessive glucose release into the bloodstream.\n\nExtended Blood Sugar Control: The sustained-release formulations of Gliclazide and Metformin ensure a gradual and prolonged release of the medications, leading to consistent blood sugar control and minimizing the risk of hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar) fluctuations.\n\nDosage and Administration:\nTRIGLICLAGLAZE 30 is typically taken orally once or twice daily, as prescribed by a healthcare provider.\nThe medication is often taken with meals to reduce the risk of gastrointestinal side effects.\nDosage adjustments may be necessary based on blood sugar levels and individual response to treatment. Follow your doctor's instructions carefully.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/trigliclaglaze-30-134278", "price": 125.0, "discountamount": 37.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "day", "body", "risk", "drugs", "meals", "Order", "liver", "cells", "EMAIL", "doctor", "muscle", "action", "pancreas", "hallmark", "treatment", "Gliclazide", "fat tissues", "information", "medications", "bloodstream", "Pioglitazone", "sterisonline", "postprandial", "hypoglycemia", "fluctuations", "instructions", "sterispharma", "Key Benefits", "hyperglycemia", "CALL/WHATSAPP", "Metformin HCL", "Metformin HCI", "glucose uptake", "Administration", "TRIGLICLAGLAZE", "low blood sugar", "gradual release", "Insulin Release", "high blood sugar", "prolonged release", "insulin secretion", "different aspects", "multiple pathways", "peripheral tissues", "insulin resistance", "Dosage adjustments", "blood sugar levels", "glucose metabolism", "glucose regulation", "glucose utilization", "individual response", "insulin sensitivity", "healthcare provider", "meal) glucose spikes", "three key components", "biguanide medication", "combination medication", "comprehensive approach", "thiazolidinedione class", "sulfonylurea medication", "type 2 diabetes mellitus", "excessive glucose release", "Hepatic Glucose Production", "overall blood sugar control", "optimal blood sugar control", "extended blood sugar control", "gastrointestinal side effects", "sustained-release formulation", "Comprehensive Glucose Control", "consistent blood sugar control", "sustained-release (SR) formulation", "consistent glucose-lowering effects" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1484, "imageuri": "https://productimages.withfloats.com/actual/6661af49f21358d53af3ccec.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661af49f21358d53af3ccec.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:44:53.071Z", "updatedon": "2024-06-28T12:15:14.626Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trigliclaglaze-30-/1484", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIGLICLAGLAZE 30 ", "category": "DIABETIC RANGE", "tags": [ "TRIGLICLAGLAZE 30", "Gliclazide (SR)", "Pioglitazone", "Metformin HCL (SR)", "Metformin SR 500mg uses", "Metformin hydrochloride 500 mg", "Metformin SR 500 side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "665ef7cfea22b014e8aefff9", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLICLAGLAZE MR 30 ", "description": "GLICLAGLAZE MR 30 \ngliclazide sr (30 mg)\nIntroduction\nGLICLAGLAZE MR 30 is specifically formulated for individuals managing Type 2 diabetes. This medication utilizes a sustained release (SR) form of Gliclazide at a 30 mg dosage, focusing on providing a steady, controlled release of the drug to maintain optimal blood sugar levels throughout the day.\n\nHow It Works\n\nGliclazide SR (30 mg): Gliclazide is a sulfonylurea class drug that increases insulin secretion from the pancreas. Unlike standard formulations, the SR version releases the medication gradually, which helps to stabilize blood sugar levels and reduces the risk of severe fluctuations that can lead to hypoglycemia. This mechanism not only enhances the body’s natural insulin use but also supports overall vascular health, decreasing the risk of complications associated with diabetes, such as cardiovascular disease.\nBenefits\nGLICLAGLAZE MR 30 is an excellent choice for patients who require a mild enhancement in their insulin secretion with a lower risk of hypoglycemia. The SR formulation provides a more predictable pharmacokinetic profile, which is crucial for maintaining a stable glycemic control. This can significantly improve the quality of life for patients by reducing common side effects associated with blood sugar spikes and drops.\n\nDosage and Administration\n\nDosage: The dose of GLICLAGLAZE MR 30 should be adjusted based on the patient’s blood glucose response and previous treatment history. Regular monitoring of blood glucose and glycated hemoglobin (HbA1c) levels is recommended to ensure that the dosage is effective.\nAdministration: This medication should be taken with breakfast or the first main meal of the day. The tablet should be swallowed whole to maintain the integrity of the sustained release mechanism.\nSide Effects\nPossible side effects of GLICLAGLAZE MR 30 include gastrointestinal issues such as nausea and upset stomach. Due to its sulfonylurea component, there is a risk of hypoglycemia, although it is generally lower compared to other sulfonylureas due to the sustained release formulation.\n\nConclusion\nGLICLAGLAZE MR 30 is a practical and effective solution for managing Type 2 diabetes, especially suited for patients seeking a gentle modification in their diabetes treatment plan with sustained drug release. It simplifies diabetes management, potentially enhancing adherence and minimizing the risk of dosage-related complications. As with any medication, consultation with a healthcare provider is essential to tailor the treatment to individual needs and conditions.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/gliclaglaze-mr-30-133422", "price": 83.0, "discountamount": 24.9, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "day", "dose", "life", "body", "drops", "EMAIL", "Order", "upset", "tablet", "nausea", "stomach", "quality", "SR) form", "patients", "Benefits", "pancreas", "adherence", "integrity", "breakfast", "practical", "lower risk", "SR version", "medication", "conditions", "Conclusion", "individuals", "information", "sterisonline", "Introduction", "30 mg dosage", "consultation", "sterispharma", "hypoglycemia", "CALL/WHATSAPP", "Gliclazide SR", "HbA1c) levels", "SR formulation", "GLICLAGLAZE MR", "first main meal", "Type 2 diabetes", "mild enhancement", "individual needs", "excellent choice", "insulin secretion", "effective solution", "Regular monitoring", "blood sugar spikes", "healthcare provider", "diabetes management", "gentle modification", "other sulfonylureas", "common side effects", "glycated hemoglobin", "severe fluctuations", "natural insulin use", "Possible side effects", "standard formulations", "Administration Dosage", "sulfonylurea component", "sustained drug release", "blood glucose response", "cardiovascular disease", "diabetes treatment plan", "stable glycemic control", "gastrointestinal issues", "overall vascular health", "sulfonylurea class drug", "steady, controlled release", "optimal blood sugar levels", "previous treatment history", "sustained release mechanism", "dosage-related complications", "sustained release formulation", "predictable pharmacokinetic profile" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1291, "imageuri": "https://productimages.withfloats.com/actual/665ef7d253245b8b6b459895.png", "tileimageuri": "https://productimages.withfloats.com/tile/665ef7d253245b8b6b459895.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-04T11:17:35.736Z", "updatedon": "2024-06-04T11:17:35.736Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/gliclaglaze-mr-30-/1291", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLICLAGLAZE MR 30 ", "category": "DIABETIC RANGE", "tags": null, "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }